AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 132.66 Increased By ▲ 3.13 (2.42%)
BOP 6.89 Increased By ▲ 0.21 (3.14%)
CNERGY 4.57 Decreased By ▼ -0.06 (-1.3%)
DCL 8.92 Decreased By ▼ -0.02 (-0.22%)
DFML 42.75 Increased By ▲ 1.06 (2.54%)
DGKC 84.00 Increased By ▲ 0.23 (0.27%)
FCCL 32.90 Increased By ▲ 0.13 (0.4%)
FFBL 77.06 Increased By ▲ 1.59 (2.11%)
FFL 12.20 Increased By ▲ 0.73 (6.36%)
HUBC 110.01 Decreased By ▼ -0.54 (-0.49%)
HUMNL 14.40 Decreased By ▼ -0.16 (-1.1%)
KEL 5.53 Increased By ▲ 0.14 (2.6%)
KOSM 8.32 Decreased By ▼ -0.08 (-0.95%)
MLCF 39.67 Decreased By ▼ -0.12 (-0.3%)
NBP 65.50 Increased By ▲ 5.21 (8.64%)
OGDC 198.74 Decreased By ▼ -0.92 (-0.46%)
PAEL 26.00 Decreased By ▼ -0.65 (-2.44%)
PIBTL 7.62 Decreased By ▼ -0.04 (-0.52%)
PPL 159.00 Increased By ▲ 1.08 (0.68%)
PRL 26.24 Decreased By ▼ -0.49 (-1.83%)
PTC 18.35 Decreased By ▼ -0.11 (-0.6%)
SEARL 82.24 Decreased By ▼ -0.20 (-0.24%)
TELE 8.12 Decreased By ▼ -0.19 (-2.29%)
TOMCL 34.40 Decreased By ▼ -0.11 (-0.32%)
TPLP 8.98 Decreased By ▼ -0.08 (-0.88%)
TREET 16.88 Decreased By ▼ -0.59 (-3.38%)
TRG 59.49 Decreased By ▼ -1.83 (-2.98%)
UNITY 27.52 Increased By ▲ 0.09 (0.33%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 10,614 Increased By 206.9 (1.99%)
BR30 31,874 Increased By 160.5 (0.51%)
KSE100 98,972 Increased By 1644 (1.69%)
KSE30 30,784 Increased By 591.7 (1.96%)

Pfizer Inc will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical, marking the biggest deal by the cash-rich drugmaker since 2016 to beef up its portfolio ahead of patent losses for some cancer drugs.

The deal, announced on Tuesday, will give Pfizer access to Biohaven’s approved rimegepant, a potential blockbuster that belong to a class of migraine treatments known as calcitonin gene-related peptide (CGRP) inhibitors.

Flush with about $32 billion in cash on hand after its success with COVID-19 drugs, Pfizer has been looking to add treatments as patents for its top-selling drugs like blood thinner Eliquis near expiration.

Pfizer Q1 revenues jump 77% to $25.7bn on Covid-19 vaccine

The company also expects sales of its COVID-19 vaccines to drop from last year’s highs.

“Investors will like this deal. Given Pfizer’s strong balance sheet, this is still a small acquisition and we would expect more such deals,” Wells Fargo analyst Mohit Bansal said in a note.

The Biohaven deal is its largest since Pfizer’s $14 billion purchase of cancer drugmaker Medivation in 2016.

Pfizer will acquire all Biohaven shares that it does not already own for $148.50 per share in cash, a 78.6% premium to last closing price. It had taken a 2.6% stake in Biohaven in November.

Biohaven shares jumped 70.1% to $141.39 before the bell, while Pfizer was trading flat at $48.60.

With this deal, Pfizer will compete in a crowded market for migraine treatments from other large drugmakers such as Eli Lilly.

Biohaven’s rimegepant, sold as Nurtec ODT in the United States, is approved for use as both a treatment and preventative for migraines and is expected to bring in sales of over $4 billion by 2030. It brought in sales of $462.5 million in 2021.

Biohaven is also developing another CGRP inhibitor and testing two non-CGRP drugs in late-stage studies.

After the deal closes, Biohaven shareholders, including Pfizer, will get 0.5 of a share of a new publicly traded company that will retain Biohaven’s non-CGRP treatments.

Comments

Comments are closed.